Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
MorphoSys price target raised to EUR 110 from EUR 105 at Barclays » 11:42
10/02/20
10/02
11:42
10/02/20
11:42
MOR

MorphoSys

$28.65 /

-1.47 (-4.88%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis raised the firm's price target on MorphoSys to EUR 110 from EUR 105 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
MOR MorphoSys
$28.65 /

-1.47 (-4.88%)

MOR MorphoSys
$28.65 /

-1.47 (-4.88%)

08/10/20 Citi
MorphoSys initiated with a Buy at Citi
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
MOR MorphoSys
$28.65 /

-1.47 (-4.88%)

Hot Stocks
MorphoSys CFO Holstein to step down effective December 31, 2020 » 16:31
09/30/20
09/30
16:31
09/30/20
16:31
MOR

MorphoSys

$31.41 /

-0.36 (-1.13%)

MorphoSys announced that…

MorphoSys announced that Jens Holstein, Chief Financial Officer, has decided to step down as CFO and member of the company's Management Board, effective December 31, 2020. Holstein will continue in his role through the end of the year to ensure an orderly transition. The company has commenced a search process to identify the future chief financial officer. "Jens Holstein has been truly instrumental in building MorphoSys to a fully integrated biopharma company, providing valuable medicines to patients suffering from serious diseases. Since joining in 2011, Jens' numerous contributions added substantially to making the company the success story that it is today. He leaves MorphoSys in a position, operationally and financially, which will allow us to continue providing much needed therapies in the years to come", said Marc Cluzel, M.D., Chairman of the Supervisory Board of MorphoSys. "I understand his wish for new challenges and on behalf of the entire Supervisory Board, I would like to thank him for his excellent contribution and wish him all the best for the future."

ShowHide Related Items >><<
MOR MorphoSys
$31.41 /

-0.36 (-1.13%)

MOR MorphoSys
$31.41 /

-0.36 (-1.13%)

08/10/20 Citi
MorphoSys initiated with a Buy at Citi
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
MOR MorphoSys
$31.41 /

-0.36 (-1.13%)

Conference/Events
Incyte and MorphoSys to hold a joint conference call » 08:25
09/29/20
09/29
08:25
09/29/20
08:25
MOR

MorphoSys

$31.57 /

+0.51 (+1.64%)

, INCY

Incyte

$90.45 /

+3.97 (+4.59%)

Incyte and MorphoSys hold…

Incyte and MorphoSys hold a joint conference call to discuss the unmet need and global opportunities for Tafasitamab in Non-Hodgkin Lymphomas on September 29 at 9 am. Webcast Link

ShowHide Related Items >><<
MOR MorphoSys
$31.57 /

+0.51 (+1.64%)

INCY Incyte
$90.45 /

+3.97 (+4.59%)

MOR MorphoSys
$31.57 /

+0.51 (+1.64%)

08/10/20 Citi
MorphoSys initiated with a Buy at Citi
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
INCY Incyte
$90.45 /

+3.97 (+4.59%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
INCY Incyte
$90.45 /

+3.97 (+4.59%)

MOR MorphoSys
$31.57 /

+0.51 (+1.64%)

INCY Incyte
$90.45 /

+3.97 (+4.59%)

INCY Incyte
$90.45 /

+3.97 (+4.59%)

Conference/Events
Incyte and MorphoSys to hold a joint conference call » 04:55
09/29/20
09/29
04:55
09/29/20
04:55
MOR

MorphoSys

$31.57 /

+0.51 (+1.64%)

, INCY

Incyte

$90.45 /

+3.97 (+4.59%)

Incyte and MorphoSys hold…

Incyte and MorphoSys hold a joint conference call to discuss the unmet need and global opportunities for Tafasitamab in Non-Hodgkin Lymphomas on September 29 at 9 am. Webcast Link

ShowHide Related Items >><<
MOR MorphoSys
$31.57 /

+0.51 (+1.64%)

INCY Incyte
$90.45 /

+3.97 (+4.59%)

MOR MorphoSys
$31.57 /

+0.51 (+1.64%)

08/10/20 Citi
MorphoSys initiated with a Buy at Citi
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
INCY Incyte
$90.45 /

+3.97 (+4.59%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
INCY Incyte
$90.45 /

+3.97 (+4.59%)

MOR MorphoSys
$31.57 /

+0.51 (+1.64%)

INCY Incyte
$90.45 /

+3.97 (+4.59%)

INCY Incyte
$90.45 /

+3.97 (+4.59%)

Conference/Events
Incyte and MorphoSys to hold a joint conference call » 17:17
09/25/20
09/25
17:17
09/25/20
17:17
MOR

MorphoSys

$31.41 /

+0.7 (+2.28%)

, INCY

Incyte

$86.48 /

+1.38 (+1.62%)

Incyte and MorphoSys hold…

Incyte and MorphoSys hold a joint conference call to discuss the unmet need and global opportunities for Tafasitamab in Non-Hodgkin Lymphomas on September 29 at 9 am. Webcast Link

ShowHide Related Items >><<
MOR MorphoSys
$31.41 /

+0.7 (+2.28%)

INCY Incyte
$86.48 /

+1.38 (+1.62%)

MOR MorphoSys
$31.41 /

+0.7 (+2.28%)

08/10/20 Citi
MorphoSys initiated with a Buy at Citi
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
INCY Incyte
$86.48 /

+1.38 (+1.62%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
INCY Incyte
$86.48 /

+1.38 (+1.62%)

MOR MorphoSys
$31.41 /

+0.7 (+2.28%)

INCY Incyte
$86.48 /

+1.38 (+1.62%)

INCY Incyte
$86.48 /

+1.38 (+1.62%)

Over a month ago
Hot Stocks
I-MAB, MorphoSys announce FDA clearance of IND for MOR210/TJ210 » 16:07
09/17/20
09/17
16:07
09/17/20
16:07
IMAB

I-MAB

$37.87 /

+1.22 (+3.33%)

, MOR

MorphoSys

$33.85 /

+0.71 (+2.14%)

MorphoSys (MOR) and I-Mab…

MorphoSys (MOR) and I-Mab (IMAB) jointly announced that the U.S. FDA has cleared the Investigational New Drug application for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors. The phase 1 clinical trial, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210, may proceed and is expected to commence subsequently. MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing agreement to develop and commercialize MOR210/TJ210 in November 2018. Under the terms of agreement, I-Mab receives exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world. With support from MorphoSys, I-Mab will also fund and conduct all global development activities of MOR210/TJ210, including clinical trials in China and the U.S., towards clinical proof-of-concept in oncology. The two companies are also collaborating on MorphoSys' investigational human CD38 antibody MOR202/TJ202. I-Mab owns the exclusive rights for development and commercialization in mainland China, Taiwan, Hong Kong and Macao and started two registrational trials to evaluate MOR202/TJ202 in patients with relapsed or refractory multiple myeloma in 2019.

ShowHide Related Items >><<
MOR MorphoSys
$33.85 /

+0.71 (+2.14%)

IMAB I-MAB
$37.87 /

+1.22 (+3.33%)

IMAB I-MAB
$37.87 /

+1.22 (+3.33%)

09/08/20 Cantor Fitzgerald
I-MAB price target raised to $55 from $50 at Cantor Fitzgerald
07/27/20 Cantor Fitzgerald
I-MAB initiated with an Overweight at Cantor Fitzgerald
02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
MOR MorphoSys
$33.85 /

+0.71 (+2.14%)

08/10/20 Citi
MorphoSys initiated with a Buy at Citi
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
MOR MorphoSys
$33.85 /

+0.71 (+2.14%)

IMAB I-MAB
$37.87 /

+1.22 (+3.33%)

  • 17
    Jan
MOR MorphoSys
$33.85 /

+0.71 (+2.14%)

IMAB I-MAB
$37.87 /

+1.22 (+3.33%)

Hot Stocks
Incyte, Morphosys announce Monjuvi included in NCCN guidelines » 16:06
08/18/20
08/18
16:06
08/18/20
16:06
INCY

Incyte

$97.49 /

+0.02 (+0.02%)

, MOR

MorphoSys

$31.98 /

-0.69 (-2.11%)

MorphoSys AG (MOR) and…

MorphoSys AG (MOR) and Incyte (INCY) announced that Monjuvi, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines, NCCN Guidelines, in Oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines in the United States now include Monjuvi in combination with lenalidomide with a Category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma who are ineligible for autologous stem cell transplant.

ShowHide Related Items >><<
MOR MorphoSys
$31.98 /

-0.69 (-2.11%)

INCY Incyte
$97.49 /

+0.02 (+0.02%)

INCY Incyte
$97.49 /

+0.02 (+0.02%)

08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
MOR MorphoSys
$31.98 /

-0.69 (-2.11%)

08/10/20 Citi
MorphoSys initiated with a Buy at Citi
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
MOR MorphoSys
$31.98 /

-0.69 (-2.11%)

INCY Incyte
$97.49 /

+0.02 (+0.02%)

MOR MorphoSys
$31.98 /

-0.69 (-2.11%)

MOR MorphoSys
$31.98 /

-0.69 (-2.11%)

INCY Incyte
$97.49 /

+0.02 (+0.02%)

INCY Incyte
$97.49 /

+0.02 (+0.02%)

Initiation
MorphoSys initiated with a Buy at Citi » 06:39
08/10/20
08/10
06:39
08/10/20
06:39
MOR

MorphoSys

$31.25 /

-1.43 (-4.38%)

Citi analyst Vineet…

Citi analyst Vineet Agrawal initiated coverage of MorphoSys with a Buy rating and EUR 160 price target.

ShowHide Related Items >><<
MOR MorphoSys
$31.25 /

-1.43 (-4.38%)

MOR MorphoSys
$31.25 /

-1.43 (-4.38%)

08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
MOR MorphoSys
$31.25 /

-1.43 (-4.38%)

MOR MorphoSys
$31.25 /

-1.43 (-4.38%)

MOR MorphoSys
$31.25 /

-1.43 (-4.38%)

Recommendations
MorphoSys FDA approval in line with expectations, says Deutsche Bank » 13:27
08/03/20
08/03
13:27
08/03/20
13:27
MOR

MorphoSys

$34.24 /

+2.13 (+6.63%)

, INCY

Incyte

$101.14 /

+2.38 (+2.41%)

Deutsche Bank analyst…

Deutsche Bank analyst Rajan Sharma reiterated a Buy rating and EUR129 price target on MorphoSys (MOR) after the company and Incyte (INCY) announced conditional FDA approval of Fc-engineered CD19 antibody tafasitamab in combination with Revlimid for the treatment of relapsed/refractory diffuse large B-cell lymphoma ahead of its August 30 PDUFA data. The analyst said that approval is in line with his expectations.

ShowHide Related Items >><<
MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
INCY Incyte
$101.14 /

+2.38 (+2.41%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

MOR MorphoSys
$34.24 /

+2.13 (+6.63%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

INCY Incyte
$101.14 /

+2.38 (+2.41%)

Recommendations
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler » 11:10
08/03/20
08/03
11:10
08/03/20
11:10
INCY

Incyte

$100.16 /

+1.4 (+1.42%)

, MOR

MorphoSys

$33.96 /

+1.855 (+5.78%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren notes that Incyte (INCY) and partner MorphoSys (MOR) hosted a call on Monday to review the approval of Monjuvi. Based on management's comments, the analyst thinks the pricing is reasonable considering the observed treatment benefit, and continues to have confidence in the upcoming Monjuvi U.S. launch given the synergies that will likely be realized by leveraging Incyte's current Jakafi infrastructure and recent experience from the Pemazyre virtual drug launch. Recall that it is a 50/50 profit share in the U.S., so substantial profit likely won't be realized until next year, but still could be a meaningful $300M profit contributor long-term, he contends. Van Buren has an Overweight rating and a price target of $110 on Incyte's shares.

ShowHide Related Items >><<
MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

07/23/20 Stifel
Incyte REACH3 'nice incremental surprise,' not narrative-changing, says Stifel
07/23/20 Piper Sandler
Piper says Incyte cements 'all-around win for Jakafi' with REACH3 results
07/20/20 Credit Suisse
Incyte price target raised to $100 from $88 at Credit Suisse
06/16/20
Fly Intel: Top five analyst initiations
MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

06/25/20 RBC Capital
MorphoSys downgraded to Sector Perform from Outperform at RBC Capital
05/13/20 Barclays
MorphoSys price target raised to EUR 105 from EUR 100 at Barclays
05/12/20 HSBC
MorphoSys upgraded to Hold from Reduce at HSBC
03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

MOR MorphoSys
$33.96 /

+1.855 (+5.78%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

INCY Incyte
$100.16 /

+1.4 (+1.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.